Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) EBT (2020 - 2022)

Historic EBT for Atea Pharmaceuticals (AVIR) over the last 3 years, with Q4 2022 value amounting to -$34.3 million.

  • Atea Pharmaceuticals' EBT fell 12829.95% to -$34.3 million in Q4 2022 from the same period last year, while for Dec 2022 it was -$119.5 million, marking a year-over-year decrease of 18622.48%. This contributed to the annual value of -$167.5 million for FY2024, which is 2410.14% down from last year.
  • Per Atea Pharmaceuticals' latest filing, its EBT stood at -$34.3 million for Q4 2022, which was down 12829.95% from -$11.9 million recorded in Q3 2022.
  • Atea Pharmaceuticals' EBT's 5-year high stood at $121.2 million during Q4 2021, with a 5-year trough of -$42.1 million in Q1 2022.
  • For the 3-year period, Atea Pharmaceuticals' EBT averaged around $1.1 million, with its median value being -$11.9 million (2022).
  • As far as peak fluctuations go, Atea Pharmaceuticals' EBT surged by 48690.94% in 2021, and later crashed by 45719.19% in 2022.
  • Over the past 3 years, Atea Pharmaceuticals' EBT (Quarter) stood at $20.7 million in 2020, then skyrocketed by 486.91% to $121.2 million in 2021, then plummeted by 128.3% to -$34.3 million in 2022.
  • Its EBT was -$34.3 million in Q4 2022, compared to -$11.9 million in Q3 2022 and -$31.2 million in Q2 2022.